EVOKE PHARMA, INC. Increase Decrease In Operating Lease Liability
EVOKE PHARMA, INC. reported Increase Decrease In Operating Lease Liability of -$58.11 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2025-11-13
- EVOKE PHARMA, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$19.37K.
- EVOKE PHARMA, INC. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$19.37K.
- EVOKE PHARMA, INC. increase decrease in operating lease liability for the quarter ending 2025-03-31 was -$19.37K.
- EVOKE PHARMA, INC. increase decrease in operating lease liability for the quarter ending 2023-12-31 was -$14.00K.
- EVOKE PHARMA, INC. increase decrease in operating lease liability for fiscal 2024 was -$6.46K.
- EVOKE PHARMA, INC. increase decrease in operating lease liability for fiscal 2023 was -$129.70K.
- EVOKE PHARMA, INC. increase decrease in operating lease liability for fiscal 2022 was -$37.02K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month | Increase Decrease In Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2025-09-30 | -$19.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$38.74K derived: sum of 2 quarters · filed 2025-11-13 | -$58.11K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | -$19.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$38.74K 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | -$19.37K 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | -$6.46K 10-K · filed 2025-03-13 | ||||
| 2023-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$53.47K derived: sum of 2 quarters · filed 2025-03-13 | -$92.03K derived: sum of 3 quarters · filed 2025-03-13 | -$129.70K 10-K · filed 2025-03-13 | -$129.07K 10-K · filed 2024-03-14 |
| 2023-09-30 | -$39.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$78.03K derived: sum of 2 quarters · filed 2024-11-07 | -$115.70K 10-Q · filed 2024-11-07 | -$140.30K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$38.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$76.23K 10-Q · filed 2024-08-13 | -$100.83K derived: sum of 3 quarters · filed 2024-08-13 | ||
| 2023-03-31 | -$37.68K 10-Q · filed 2024-05-14 | -$62.27K derived: sum of 2 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$24.60K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | -$37.02K 10-K/A · filed 2024-05-14 | |||
| 2022-09-30 | -$12.43K 10-Q · filed 2023-11-09 |